A newly identified mechanism lends credence to the idea that MS may be treatable by targeting EBV-infected B-cells, a study found.

ImmunityBio’s stock rose nearly 40% after it announced the Phase I data and Anktiva sales figures for 2025.

Results from two clinical trials on ianalumab for Sjögren disease show favorable safety and adverse event outcomes, ...

Ianalumab targets the BAFF receptor, depleting malignant B cells and enhancing ibrutinib's efficacy, offering a potential ...

A deep dive into the Fc–FcR axis as a therapeutic anchor in autoimmune disease, examining immune signaling and drug ...

The growing use of immuno-oncology, advancing bioinformatics analysis, and rising investment in precision medicine are driving the immune repertoire sequencing market.Austin, Texas, Jan. 22, 2026 ...

Novartis intends to submit ianalumab for regulatory approval globally in early 2026.

Although rheumatologists consider chimeric antigen receptor T-cell therapy “potentially transformative,” nearly 70% remain ...

A mouse study suggests estrogen may increase gut pain by activating specific cells, offering hints to why IBS is more common ...

Ianalumab receives FDA Breakthrough Therapy status for Sjögren disease following positive findings from two phase 3 clinical trial programs.

Autoimmune diseases arise when the immune system mistakenly targets and damages the body’s cells and tissues as though they ...

Forget hot flashes and period changes. This one overarching issue is the real menace when dealing with perimenopause.